Reconstitution of the Ataxia-Telangiectasia Cellular Phenotype With Lentiviral Vectors

Diana Carranza¹, Sara Torres-Rusillo¹*, Gloria Ceballos-Pérez¹, Eva Blanco-Jimenez², Martín Muñoz-López², José L. García-Pérez²,³ and Ignacio J. Molina¹,⁴

¹ Institute of Biopathology and Regenerative Medicine, Center for Biomedical Research, University of Granada, Granada, Spain, ² Genomic Medicine Department, Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Spain, ³ Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom, ⁴ Instituto de Investigación Biosanitaria ibs.GRANADA, Granada University Hospitals, University of Granada, Granada, Spain

Ataxia-telangiectasia (A-T) is a complex disease arising from mutations in the ATM gene (Ataxia-Telangiectasia Mutated), which plays crucial roles in repairing double-strand DNA breaks (DSBs). Heterogeneous immunodeficiency, extreme radiosensitivity, frequent appearance of tumors and neurological degeneration are hallmarks of the disease, which carries high morbidity and mortality because only palliative treatments are currently available. Gene therapy was effective in animal models of the disease, but the large size of the ATM cDNA required the use of HSV-1 or HSV/AAV hybrid amplicon vectors, whose characteristics make them unlikely tools for treating A-T patients. Due to recent advances in vector packaging, production and biosafety, we developed a lentiviral vector containing the ATM cDNA and tested whether or not it could rescue cellular defects of A-T human mutant fibroblasts. Although the cargo capacity of lentiviral vectors is an inherent limitation in their use, and despite the large size of the transgene, we successfully transduced around 20% of ATM-mutant cells. ATM expression and phosphorylation assays indicated that the neoprotein was functional in transduced cells, further reinforced by their restored capacity to phosphorylate direct ATM substrates such as p53 and their capability to repair radiation-induced DSBs. In addition, transduced cells also restored cellular radiosensitivity and cell cycle abnormalities. Our results demonstrate that lentiviral vectors can be used to rescue the intrinsic cellular defects of ATM-mutant cells, which represent, in spite of their limitations, a proof-of-concept for A-T gene therapy.

Keywords: Ataxia-Telangiectasia, gene therapy, lentiviral vectors, monogenic diseases, cell reconstitution, Primary immunodeficiency

INTRODUCTION

A-T (MIM# 208900) patients have cerebellar ataxia, heterogeneous immunodeficiency, frequent appearance of tumors, extreme radiosensitivity, endocrine abnormalities, incomplete sexual maturation, premature aging and vascular telangiectasias and impaired capacity to repair DSBs (1–4). This autosomal recessive disease is caused by mutations in the ATM gene (5), a key regulator in cell cycle and DNA repair mechanisms (1, 2). This gene, which contains 66 exons spanning over 150 kb of the genome with an open reading frame of 9,168 bp (6), encodes the 370 kDa ATM protein (5). Inactive ATM is found as dimers or tetramers that can be activated when recruited and
and cell cycle abnormalities (human fibroblasts resulted in functional expression of the amplicon vectors (studies relied on the use of Herpes Simplex Virus Class 1 (HSV-1) used vectors such as oncoretroviruses. This is why previous limitations of the existing A-T animal model. Although the ataxic, and therefore, do not recapitulate the hallmark defect found in A-T patients, it is unfortunate that they are not currently under intense scrutiny (4). Because of these limitations and biosafety concerns, gene therapy prospects for A-T patients remain somber.

Lentiviral vectors transduce resting cells without previous stimulation or addition of cytokines, can avoid silencing when controlled by adequate promoters and show little genotoxicity (24). Although lentiviral titers diminish as the size of the cDNA increases (25), some methods allow the production of lentiviral vectors containing large inserts (26). Third-generation lentiviral vectors consist, in addition to the therapeutic plasmid, in two separate packaging plasmids and another encoding the envelope protein (27). Although not completely risk-free, it is generally accepted that these vectors have improved biosafety because the probability of viral recombination is diminished (28), and therefore, are clinically relevant. In this study we demonstrate that, despite relatively modest viral titers, our lentiviral vector reconstitutes the ATM cellular phenotype, an initial step for the development of future preclinical studies for gene therapy in A-T patients.

METHODS

Cells and Culture Media
GM07481 A-T fibroblasts, bearing an uncharacterized ATM mutation, were obtained from the Coriell Institute (Camden, NJ), whereas their healthy counterparts HFF-1 were from ATCC (SCRC-1041) and were both maintained in high-glucose DMEM media (Gibco, Paisley, United Kingdom), supplemented with 10% Fetal Bovine Serum (FBS) (Gibco), 1 mM L-glutamine and 10% Fetal Bovine Serum (FBS) (Gibco). 1 mM L-glutamine and 100 µg/ml of penicillin-streptomycin. The amphotropic Phoenix-AMPHO cells and the human embryonic kidney (HEK) 293T cells were cultured as above.

Lentiviral Vector Construction and Production
To construct the ATM lentiviral vector, the full-length ATM cDNA contained in a pcDNA3.1 plasmid (Addgene, #31985, Cambridge, MA) was excised and inserted by a three-step subcloning strategy into the lentiviral plasmid pThOKSIM to generate the pThATM plasmid (Figure 1A) under the control of the human elongation factor 1 alpha (EFla) promoter. Viral particles were produced by co-transfecting HEK 293T cells with plasmids pThATM, pHDM.G, pHDM-Tat, pRC/Rev, and pHDM-Hmg2, encoding for the AT; Vesicular Stomatitis Viral G-protein (VSV-G); trans-activator of transcription (tat); regulator of expression of virion proteins (rev); and group antigen/polymerase (gag/pol) products, respectively (19.2; 1.92; 0.96, and 0.96 µg of plasmid DNA) using lipofectamine-2000 (Invitrogen). Viral particles were collected, concentrated by ultracentrifugation (29, 30) and used immediately.

Generation of Normal and ATM-Deficient Human Immortalized Fibroblasts (HIFs)
The catalytic subunit of human telomerase on vector pBABE-hygro-hTERT plasmid (Addgene, #1773) was packaged into retroviral particles at 32°C using the amphotropic Phoenix A cell line and Fugene-6 (Promega, Madison, WI). Wild Type and ATM-mutant HIFs were transduced and resistant colonies pooled and expanded after 15 days of hygromycin selection (Sigma Chemical, Saint Louis, MO).
Transduction of Cells
ATM-deficient HIFs were seeded in 24-well plates (7.5 × 10⁴ cells/well) and 24 h later viral supernatants were added in the presence of 5 μg/ml of polybrene (Sigma).

Antibodies
The following monoclonal antibodies (mAbs) were used: anti-ATM 1A1 (Santa Cruz Biotechnology, Santa Cruz, CA); anti-ATM pSer1981 mAb (10H11E12, Rockland, Givertsville, PA); anti-NBS1 (34/NBS1, BD Biosciences, San Jose, CA); anti-p53 (DO-1; Sigma); rabbit antiserum against phosphorylated p53 on Ser15 (p-p53) was obtained from Santa Cruz Biotechnology and rabbit polyclonal anti-γ-H2AX from Abcam (Cambridge, U.K.). The Hoechst 33342 reagent and the AlexaFluor 488 goat anti-mouse or goat anti-rabbit secondary antibodies were obtained from LifeTechnologies. Goat and mouse normal sera used in blocking steps were from Sigma.

Lentiviral Vector Titration
Lentiviral vector titration was determined on genomic DNA (gDNA) by quantitative PCR (qPCR) as described (29, 31). Briefly, 293T cells were transduced as above with 1, 10, or 100 μl of viral supernatants, and after media replacement, were allowed to grow for 3 weeks prior gDNA extraction and analysis. Results were expressed as vector genomes/ml.

PCR Analysis of gDNA and Calculation of Number of Integrations Per Cell
gDNA was isolated using the QIAamp DNA mini kit (Qiagen, Valencia, CA) 3 weeks after transduction of cells to avoid interference with non-integrated vectors. Confirmation of plasmid integration was determined by end-point PCR whereas the number of vector integrations per cell was determined by qPCR. gDNA (0.1 μg) was amplified using primers spanning vector-specific and ATM sequences: Forward: 5′-GACGATGACGACAAGATGCA-3′ and Reverse: 5′-TTTGGAATCTGAATGCCGAT-3′. End-point PCR conditions were: [5 m 95°C; 35x (45 s 95°C; 1 m 57°C; 1.5 m 72°C); 13 m 72°C]. The 116-bp PCR product was resolved in a 2% agarose gel, purified and sequenced. For qPCR, 0.2 μg of gDNA was amplified in a 7500 Real-Time PCR System (Applied Biosystem, Foster, CA) using the Fast Start Universal SYBR Green Master (Roche). qPCR was performed on transduced cells using the vector-specific primers indicated above, whereas gDNA from wild type cells was amplified with a pair of validated primers spanning ATM intron 23 and exon 24 as follows: F-ATM-I23: 5′-TGTTCCAGGACACGAAGGGAGA-3′ and R-ATM-E24: 5′-CAGGGTTCTCAGCACTATGGGA-3′. qPCR conditions were [2 m 95°C; 40x (20 s 95°C; 30 s 60°C; 30 s 72°C)]. Human β-actin was used to determine the human allele copy number in each allele and amplified using primers: F-ACT: 5′-AGCCTCGCTTTGGCGGATGC-3′ and R-ACT: 5′-ACATGGCGAGCCGTTGTCG-3′. The number of vector integrations was calculated by interpolation from a standard
curve constructed using 10-fold increases (from 10 to $10^7$ copies) of plasmid ThATM.

**Analysis of RNA**

Total RNA was extracted from transduced and ATM-deficient cells using TRIzol (Invitrogen), reverse transcribed with the High-Capacity cDNA reverse transcription kit (Applied Biosystems) and analyzed by end-point and quantitative PCR using the primers indicated above. Conditions for end-point PCR were [4 m 94°C; 35x (20 s 94°C; 20 s 52°C; 45 s 72°C); 10 m 72°C] and for qPCR [10 m 95°C; 40x (30 s 95°C; 60 s 55°C; 60 s 72°C)].

**Western Blotting Analyses**

Nuclear lysates from cells non-irradiated and irradiated with a $^{137}$Cs MARKI irradiator (JL Shepherd, San Fernando, CA) were extracted using the NER-PER™ system (Life Technologies) following manufacturer’s instructions. Solubilized extracts (50 μg per lane) were loaded onto 4%-15% Mini Protean TGX Precast gels (BioRad), electrophoresed and electrotransferred onto a PVDF membrane (Trans-Blot Turbo Transfer system, BioRad) following manufacturer’s recommendations for high m.w. proteins. Membranes were blocked with 10% non-fat milk in 0.1% PBS/Tween 20 or TTBS (50 mM TRIS, 150 mM NaCl, pH 7.6) for 1 h and incubated overnight with pre-determined optimal concentrations of primary antibodies; after washes, membranes were incubated with secondary antibodies for 1 h at room temperature (RT), developed by chemiluminescence (SuperSignal West Femto, Thermo Scientific), recorded with a digital imaging system (Fujifilm Image Analyzer LAS-4000, Tokyo, Japan) and analyzed with the MultiGauge software.

**Confocal Microscopy**

Cells were pre-seeded in 8-well chamber slides (30 × 10^3 per well), irradiated and cultured for indicated times. For γ-H2AX staining, cells were starved for 12 h prior irradiation. Cells were fixed at end-points with either 3% paraformaldehyde and 2% sucrose for 10 m or 100% methanol for 10 m (for γ-H2AX immunostaining), permeabilized, blocked and incubated with primary antibodies in PBS supplemented with 2% Bovine Serum Albumin and 10% normal goat serum and 0.3 M glycine (for γH2AX staining). After washes, cells were incubated with Alexa Fluor 488-labeled secondary antibodies for 1 h at RT. Cell nuclei were counterstained with Hoescht 33342 (Thermo Fisher). Confocal microscopy used a Zeiss LSM 710 Confocal Laser Scanning Microscope. At least 200 nuclei from each sample were counted and those containing ≥4 foci were considered positive. Results are reported as number of foci per cell (average of total foci counted/average of total nuclei); percentages of cells with foci (for p-ATM and p-p53) or percentage of repairing cells (for γ-H2AX) (% Repairing cells = ∑Total counted nuclei/∑nuclei positive).

**Colony Survival Assays**

In vitro radiosensitivity assays were performed as described (32) using increasing numbers of cells (from 500 to 10,000 for normal and transduced cells; 4,500 to 30,000 for untransduced). Cells were irradiated and cultured for 2 weeks, fixed in PBS/0.5% formaldehyde/5% glutaraldehyde, stained with crystal violet and photographed. Clusters containing over 50 cells were considered colonies (123 pixels) as analyzed with ImageJ software. The total area occupied by colonies produced by irradiated cells was quantified and compared to that from untreated cells in each group. Statistical analysis and survival fractions (SF) were calculated as described (32). According to established values (33), cells were considered radiosensitive (SF<21%); intermediate radiosensitivity (SF 21-35%) or normal (SF≥36%).

**Cell Cycle Analyses**

Cells were irradiated with 4 Gy, cultured for 18 h and cell cycle profiles were determined by flow cytometry after Propidium Iodide staining as described elsewhere (34) using a BD FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA).

**RESULTS**

**Transduced Human-Immortalized Fibroblasts (HIFs) From A-T Patients Express a Functional ATM Protein**

To test whether or not A-T patients could benefit from integrative gene therapy, we constructed a third-generation lentiviral plasmid containing the ATM cDNA (pThATM; Figure 1A). Vector packaging typically yielded $5 \times 10^6$ vector genomes/ml after viral concentration as indicated. HIFs from A-T patients or healthy individuals (WT) (35) were established, transduced with increasing MOIs (Figure 1B) and vector integration efficiency determined using pThATM-specific primers. Amplification of exogenous ATM was detected only in transduced cells, whereas amplification products were not observed in neither untransduced nor WT cells (Figure 1B). Cells transduced at MOI=5 integrated 0.4 copies of exogenous ATM per cell, and the resulting cell line was used, for consistency, throughout the study. Notably, integrated vectors efficiently transcribed the ATM transgene in a dose-dependent manner, as detected by RT-PCR (Figure 1C). Nuclear extracts from HIFs cells were analyzed by Western Blotting, and expression of the ATM protein was detected in mutant cells after lentiviral transduction, although ATM expression was weaker than that of WT control cells (Figure 1D, top panel). The lentiviral-expressed ATM protein was functionally active, as demonstrated by the appearance of p-ATM upon irradiation of transduced cells (Figure 1D, bottom panel).

To estimate the percentage of reconstituted cells upon transduction, we used confocal microscopy to detect p-ATM foci before and after ionizing irradiation. Irradiated untransduced cells had no detectable p-ATM foci, whereas, at stark contrast, these were readily detected in transduced cells (Figure 2A). Blind quantification of the number of cells containing p-ATM foci (Figure 2B, left-hand graph), as well as, the number of foci per cell (Figure 2B, left-hand graph) indicated that p-ATM foci were found in 19.3 ± 5.1% of transduced cells and in 50.8 ± 5.1% of WT cells treated in parallel as controls (Figure 2B, left hand graph). The average number of ATM foci in reconstituted cells
A-T Deficient Cells Transduced With ThATM Lentiviruses Can Repair Irradiation-Induced DSBs

The tumor suppressor gene p53 is a direct downstream substrate of ATM (10). Because of this, and to accumulate evidence about the functionality of the ThATM vector, we tested whether ATM-mediated p53 phosphorylation could be detected in transduced cells upon γ-irradiation. As expected, intranuclear foci of p-p53 were observed in irradiated WT cells, indicating accumulation of activated p53 on chromatin (Figures 3A,B, left-hand top panels and graph). However, and because p53 is not exclusively phosphorylated by ATM, a residual activation of p53 was also distinguished in irradiated ATM-deficient cells (Figures 3A,B; top central panels and right-hand bottom graph). The fluorescence intensity detected in untransduced cells was much lower than that observed in WT HIFs, even though p-p53 foci were detected in about 40% of cells. We observed that transduced cells had a higher percentage of p-p53 foci, which was consistent with the estimated percentage of cells efficiently transduced; additionally, a clear increase in the fluorescence intensity of p-p53 foci was observed (Figure 3B, left-hand graph). These results were confirmed by western-blotting, revealing the appearance of a clear p-p53 band in transduced cells upon irradiation (Figure 3B). Expression levels of p-p53 correlated with the transduction efficiency of HIFs, although p-p53 expression values were lower than those of WT cells (Figure 3C). As expected, only traces of p-p53 could be detected in untransduced cells.
Irradiation-induced DSBs result in phosphorylation of the specialized histone H2AX on Ser139 [i.e., γ-H2AX (36)]. Phosphorylated γ-H2AX induces the formation of protein conglomerates of damage sensors in the proximity of the lesions that can be detected as intranuclear γ-H2AX foci, whose formation is a critical step to efficiently trigger DNA repairing mechanisms. These γ-H2AX foci were detected in all cells 30 m after irradiation (Figure 4A, central column), and no differences were observed in the number of γ-H2AX foci per cell among WT (12.3 ± 3.8), untransduced (12.7 ± 3.9), or transduced (12.9 ± 3.7) HIFs (Figure 4B, left-hand graph). γ-H2AX is gradually dephosphorylated upon repairing of the induced DSBs. Whereas, γ-H2AX foci persisted 24 h after irradiation of untransduced A-T HIFs, these foci were no longer detected 24 h after irradiating WT or transduced HIFs (Figure 4A, right-hand top and bottom panels; Figure 4B, right-hand graph). Indeed, the persistence of γ-H2AX foci in 58.47 ± 4.96 untransduced cells strongly suggests that DSBs remain unrepair (Figure 4A, right-hand central panel and Figure 4B, right graph).

**ATM Deficient Cells Transduced With ThATM Lentiviruses Restore the Radiosensitivity Defect**

Because radiosensitivity is a hallmark of both A-T patients and cultured A-T cells (37), we performed colony-survival assays to determine whether ThATM lentiviral transduction rescue ATM-deficient cells from this defect. As expected, Napierian logarithm value analyses of the survival fraction of irradiated cells revealed a strong radiosensitivity of A-T HIFs (UTD, Figure 5, left graph). Transduction of A-T-derived cells with the ThATM lentiviral vector revealed a significant increase in the fraction of surviving cells (TD, Figure 5). Transduced HIFs reversed their inherent radiosensitivity to levels approaching those observed in WT cells (Figure 5).

**Cell Cycle Abnormalities Are Restored in Cells Transduced With ThATM Lentiviruses**

Because ATM is a key regulator of cell cycle checkpoints, particularly those operating at G1/S and G2/M interphase, cells from A-T patients are normally arrested at G2/M phase 24 h after irradiation (38). We therefore studied whether or not these defects could also be restored in lentiviral-transduced A-T HIFs cells. The quantification of accumulated cells at G2/M phase is estimated by the ratio of G2-M/G0-G1, previously used to demonstrate ATM functional reconstitution of defective cells (15). As expected, untransduced A-T HIFs cells were arrested at the G2/M phase 18 h post-irradiation, as revealed by a G2-M/G0-G1 ratio of 0.62 ± 0.08 (Figure 6). In sharp contrast, WT cells progressed through cell cycle and had a much lower ratio (G2-M/G0-G1 = 0.12 ± 0.03). Transduced cells, importantly, showed an intermediate G2-M/G0-G1 ratio (G2-M/G0-G1 = 0.36 ± 0.11), consistent with the estimated percentage of transduction efficiency achieved with ThATM lentiviruses (Figure 6).

**DISCUSSION**

A-T patients sustain a high morbidity and mortality because of the severity of the disease and the lack of effective treatments. Although several organs are affected, abnormalities in hematopoietic cells play prominent roles in the general context of the disease (1). Reconstitution of hematopoietic bone marrow progenitors in a murine model of the disease resulted in extended lifespan of transplanted mice (18), and two recent reports described significant clinical benefits in two A-T patients who received a bone marrow transplant to treat concomitant Acute Lymphoblastic Leukemia (39) and non-Hodgkin lymphoma (40).

Recent improvements on gene delivery vectors are the basis to evaluate the efficacy of gene therapy protocols in the treatment of complex diseases such as A-T. Indeed, the delivery of the ATM cDNA into mutant mice was successful (15, 19) and amelioration of neurological symptoms after intracranial vector injection was observed (17). The vectors used, HSV-1 and HSV/AAV amplicons, were efficient in packaging the large ATM cDNA but, unfortunately, their characteristics (summarized in the introduction) make them unlikely tools to treat A-T patients.
due to their challenged biosafety (22) and non-integration into the host genome.

We constructed a third-generation lentiviral vector (27) containing the ATM cDNA to test whether or not this vector was able to rescue A-T cell functions in vitro. HIFs were chosen as targets because they represent a stable experimental system that mimic the intrinsic defects of the disease observed in primary A-T cells (35). Vector integration into mutant cells resulted in expression of a functional ATM protein, as revealed by its phosphorylation upon irradiation, a key indicator of a correct activation. Moreover, confocal microscopy detected p-ATM foci of normal shape in more than 20% of cells, which is consistent with the lentiviral titers and vector copy numbers achieved and the expected transduction efficiency.

The analysis of γ-H2AX foci is considered a new cornerstone assay to evaluate ATM function because its sensitivity and reproducibility (41, 42). The restoration of this function in transduced cells and their capacity to phosphorylate the ATM-direct substrate p53 are further evidence that transduced cells were repaired by the therapeutic vector generated in this study. Upon recruitment of γ-H2AX at DSBs the cascade of DNA repair processes is triggered. Whereas 24 h after irradiation γ-H2AX foci could be detected in ATM-deficient cells, suggesting the presence of abundant unrepaired DSBs, these foci were not detectable in ATM-transduced cells. This is an indication that complementation with the vector generated in this study resets cells to a pre-damage homeostatic dephosphorylated situation (43). The ability of transduced cells to repair DSBs was reinforced by the reversal of the A-T radiosensitivity and cell cycle abnormalities. The levels of rescue and complementation of A-T defects observed with ThATM are similar to that previously observed in studies that treated ATM-deficient cells with small molecule compounds that allow read-through over Premature Termination Codons (PTCs) (42, 44). Unfortunately, the percentage of patients suffering from A-T due to the presence of PTCs in the ATM gene that could benefit from this chemical treatment is very low in some cohorts (45), and hence, gene therapy should be considered as an alternative and perhaps better therapeutic option.

Our results indicate that although lentiviral titers are low because of the size of the ATM cDNA, gene therapy reconstitutes cellular defects of A-T cells. A recent study showed that lentiviral vectors can also rescue defective Duchenne Muscular Dystrophy cells, but because the size of the dystrophin gene is even higher than that of ATM (15 kb), viral titers were concurrently lower than those obtained in this work (46). Gene therapy for A-T showed promise after correcting hematopoietic progenitors in animal models of the disease, further reinforced by the outcome of bone marrow transplants performed in A-T patients due to concomitant hematopoietic malignancies (39, 40). Although the disease is not restricted to the hematopoietic system, this treatment led, surprisingly, to an improvement of the neurological defects. This unexplained observation suggests

FIGURE 5 | Colony Survival Assays showing restoration of radiosensitivity in A-T HIFs transduced with the lentiviral ThATM vector. WT and A-T HIFs (untransduced and transduced) were irradiated with each indicated doses and Colony Survival Assays were carried out in triplicates. Colony numbers were calculated using ImageJ software. The left graph represents the Naesperian Logarithm of the survival fraction adjusted to a linear model; and the right graph represents the survival fraction upon 1 Gy irradiation. Results were normalized to the data obtained with non-irradiated cells for each group, and assigned a value of 1. *p < 0.05 using the two-tailed t-test for paired observations. All other group comparisons showed non-significant differences. WT, HIFs derived from healthy subjects; UTD, untransduced A-T HIFs; TD, A-T HIFs cells transduced with the ThATM lentiviral vector.

FIGURE 6 | Reconstitution of cell cycle abnormalities in A-T HIFs transduced with the ThATM lentiviral vector. WT and A-T HIFs (untransduced and transduced) were irradiated with 4 Gy and further cultured for 18 h prior to analyse their cell cycle phases distribution by flow cytometry (using propidium iodide staining, see Methods). The percentage of cells in each phase of the cell cycle was determined and the graph shows the mean ± S.D of the G2-M/G0-G1 ratio of three independent experiments. **p < 0.01; ***p < 0.001 using the two-tailed t-test for paired observations. All other group comparisons showed non-significant differences. WT, HIFs derived from healthy subjects; UTD, untransduced A-T HIFs; TD, A-T HIFs cells transduced with the ThATM lentiviral vector.
pleiotropic clinical benefits derived from reconstituting the hematopoietic system, which should be interpreted within the newly proposed ATM functions extending beyond DNA repair (47–49). Because of this systemic effect, it is possible to speculate that gene therapy could ameliorate neurological functions in A-T patients. In addition, and as demonstrated in animal models (50), lentiviral vectors could, in theory, be delivered into the brain of A-T patients to reach Purkinje cells. Human clinical trials, however, require sharp improvements in viral packaging efficiency. Fortunately, continuous efforts are currently underway in this area, including the development of stable packaging cell lines (51) or codon-optimized vectors. On the other hand, it is possible that low-levels protein expression will nevertheless result in clinical benefit for the patients. In support of this idea is the fact that leaky functional expression (as little as 9% of the protein levels found in normal cells) of the mutated gene causing certain primary immunodeficiencies such as the Wiskott-Aldrich syndrome, resulted in a mild presentation of the disease (52). This is also the case of A-T, where an elegant study of a large cohort of patients demonstrated that those individuals retaining residual ATM kinase activity presented mild clinical symptoms, with greatly diminished neurological affection and prolonged survival (53).

In summary, we provide evidence that a third-generation lentiviral vector containing the ATM cDNA is able to reconstitute disease-associated defects in transduced patient cells. In spite of the efficiency limitations due to the large size of the transgene, our results are proof-of-concept for integrative gene therapy in A-T, an approach that requires further studies to pave its way for future trials in humans. Although fibroblasts are relatively permissive cells, the transduction efficiency achieved in hematopoietic precursors is moderately lower. Nevertheless, improving the delivery efficiency in hematopoietic precursors, as well as obtaining solid in vivo data in an animal model that does not faithfully mimics the human disease are significant hurdles and key areas for immediate work.

ETHICS STATEMENT

Human cells were obtained from public repositories and handled according to the recommendations of the University of Granada’s Ethics Committee on Human Experimentation. Primary cells or tissues were not used in this study, and therefore a consent to participate is not applicable.

AUTHOR CONTRIBUTIONS

DC, ST-R, GC-P, EB-J, and MM-L performed experiments. JLG-P and IJM directed research and wrote the paper.

FUNDING

This work was supported by grant 12UDG01-ATF from Sparks, The Children’s Medical Charity, London, U.K., in coordination with Action for A-T and the Ataxia-Telangiectasia Society, U.K. DC had a fellowship from the Department of Science and Innovation, Regional Government of Andalucía, Spain. ST-R had a research contract funded by the Sparks grant, U.K. JG-P’s laboratory is funded by CICE-FEDER-PI2-CTS-2256, Plan Nacional de I+D+I 2013–2016 (FIS-FEDER-PI14/02152), PCIN-2014-115-ERA-NET NEURON II, the European Research Council (ERC-Consolidator ERC-STG-2012-233764), by an International Early Career Scientist grant from the Howard Hughes Medical Institute (IECS-55007420) and by The Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund (ISSF2). MM-L also acknowledges funding through Consejería de Salud de la Junta de Andalucía (PeS-PI-0224-2011).

ACKNOWLEDGMENTS

We are grateful to Drs. Mariano Ruiz de Almodóvar and Virgine de Araujo-Farias for help and discussions with the radiosensitivity experiments. We thank Dr. Gustavo Ortiz-Ferron from the University of Granada’s Centre for Scientific Instrumentation for expert assistance with flow cytometry and Raquel Marrero from the Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO) for invaluable help with the confocal microscopy experiments. We also acknowledge Dr. José Cibelli (Larcell, Malaga, Spain) for providing the ThOSKIM plasmid.

REFERENCES

1. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. (2008) 9:759–69. doi: 10.1038/nrm2514
2. de Miranda NF, Bjorkman A, Pan-Hammarstrom Q. DNA repair: the link between primary immunodeficiency and cancer. Ann N Y Acad Sci. (2011) 1246:50–63. doi: 10.1111/j.1749-6632.2011.06322.x
3. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med. (2012) 366:636–46. doi: 10.1056/NEJMra1006610
4. Chaudhary MW, Al-Baradie RS. Ataxia-telangiectasia: future prospects. Appl Clin Genet. (2014) 7:159–67. doi: 10.2147/TACG.S35759
5. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (1995) 268:1749–53. doi: 10.1126/science.7792600
6. Uziel T, Savitsky K, Platzer M, Ziv Y, Helbitz T, Nehls M, et al. Genomic organization of the ATM gene. Genomics (1996) 33:317–20. doi: 10.1006/geno.1996.0201
7. Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene (2007) 26:7749–58. doi: 10.1038/sj.onc.1210880
8. Dupre A, Boyer-Chatenet L, Gautier J. Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex. Nat Struct Mol Biol. (2006) 13:451–57. doi: 10.1038/nsmb1090
9. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene (2007) 26:7741–48. doi: 10.1038/sj.onc.1210872
10. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 281:1677–79. doi: 10.1126/science.281.5383.1677
11. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 281:1674–77. doi: 10.1126/science.281.5383.1674

12. Kastan MB, Zhan Q, d’Deiriy WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 71:587–97. doi: 10.1016/0092-8674(92)90593-2

13. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. (2001) 276:4246–67. doi: 10.1074/jbc.C100466200

14. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. (2013) 14:197–210. doi: 10.1038/nrm3546

15. Cortes ML, Bakkenist CJ, Di Maria MV, Kastan MB, Breakefield XO. HSV-1 ampiclon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Ther. (2003) 10:1321–27. doi: 10.1038/sj.gt.3301996

16. Qi J, Shackelford R, Manusza R, Cheng D, Smith M, Link CJ, et al. Functional expression of ATM gene carried by HSV ampiclon vector in vitro and in vivo. Gene Ther. (2004) 11:25–33. doi: 10.1038/sj.gt.3302140

17. Cortes ML, Oehmig A, Perry KE, Sanford JD, Breakefield XO. Expression of human ATM cDNA in ATM-deficient mouse brain mediated by HSV-1 ampiclon vector. Neurosci. (2006) 141:1247–56. doi: 10.1016/j.neuroscience.2006.05.055

18. Bagley J, Cortes ML, Breakefield XO, Jacomini J. Bone marrow transplantation restores immune system function and prevents lymphoma in ATM-deficient mice. Blood (2004) 104:572–78. doi: 10.1182/blood-2003-12-4246

19. Cortes ML, Oehmig A, Saydam O, Sanford JD, Perry KE, Fraefel C, et al. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid ampiclon vector. Mol Ther. (2008) 16:811–8. doi: 10.1038/sj.mt.6300338

20. Lim F, Khaliq H, Ventosa M, Baldo A. Biosafety of gene therapy vectors derived from herpes simplex virus type 1. Curr Gene Ther. (2013) 13:478–91. doi: 10.2174/156652321306140103224550

21. Chandler RJ, Sands MS, Venditti CP. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models. Hum Gene Ther. (2017) 28:314–22. doi: 10.1089/hum.2017.009

22. Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe radiosensitivity of human CD40L proximal promoter sequences. J Biol Chem. (2003) 278:20492–500. doi: 10.1074/jbc.M306208200

23. Binet S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair (2008) 7:1028–38. doi: 10.1016/j.dnarep.2008.03.006

24. Romero Z, Torres S, Cobo M, Munoz P, Unciti JD, Martin F, et al. A tissue-specific, activation-inducible, lentiviral vector regulated by a human CD40L endogenous promoter. J Gene Med. (2015) 17:219–28. doi: 10.1002/jgm.2837

25. Lai CH, Chun HH, Mitui M, Gamo KM, Du L, et al. Correction of ATM gene function by aminoglycoside-induced read-through vectors can be used for full-length dystrophin gene therapy. J Gene Med. (2013) 15:2038–46. doi: 10.1002/jmg2.10169

26. Al-Yacoub N, Romanowska M, Haritonova N, Foerster J. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med. (2007) 9:579–84. doi: 10.1002/jgm.1052

27. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. (1998) 72:8463–71.

28. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia (2018) 32:1529–41. doi: 10.1038/s41375-018-0106-0

29. Romero Z, Torres S, Cobo M, Munoz P, Unciti JD, Martin F, et al. A tissue-specific, activation-inducible, lentivector regulated by human CD40L proximal promoter sequences. Gene Ther. (2011) 18:364–71. doi: 10.1038/gt.2010.144

30. Ichim CV, Wells RA. Generation of high-titer viral preparations by concentration using sucrose rounds of ultracentrifugation. J Transl Med. (2011) 9:137. doi: 10.1186/1479-5876-9-137

31. Fernandez-Rubio P, Torres-Rusillo S, Molina JI. Regulated expression of murine CD40L by a lentiviral vector transcriptionally targeted through its endogenous promoter. J Gene Med. (2015) 17:219–28. doi: 10.1002/jgm.2837
51. Sanber KS, Knight SB, Stephen SL, Bailey R, Escors D, Minshull J, et al. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep. (2015) 5:9021. doi: 10.1038/srep09021

52. Lutsiky MI, Rosen FS, Remold-O’Donnell E. Genotype-proteotype linkage in the Wiskott-Aldrich syndrome. J Immunol. (2005) 175:1329–36. doi: 10.4049/jimmunol.175.2.1329

53. Verhagen MM, Last JI, Hogervorst FB, Smeets DE, Roeleveld N, Verheijen F, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. (2012) 33:561–71. doi: 10.1002/humu.22016

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Carranza, Torres-Rusillo, Ceballos-Pérez, Blanco-Jimenez, Muñoz-López, García-Pérez and Molina. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.